Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

Adaptimmune Therapeutics plc. (5/2/17). "Press Release: Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference". Philadeliphia, PA & Oxford.

	Region	Boston, MA
	Country	United States (USA)
	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Organisation 2	Deutsche Bank (Group)
	Product	Deutsche Bank Annual Health Care Conference 2017 Boston
	Product 2	SPEAR™ T-cell therapy
	Person	Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
	Person 2	Miller, Juli P. (Adaptimmune 201808 Director Investor Relations)

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 1:10 PM EDT (6:10 PM BST). The conference is being held at the InterContinental Boston Hotel in Boston, MA. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com

Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

Record changed: 2023-06-05